LHCQX Mutual Fund

LHCQX Mutual Fund

NAV$24.32
See how much of LHCQX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Apr 30, 2026

Net Assets
-
Expense Ratio
1.28%
Dividend Yield (Current)
-
Holdings
64
Inception Date
Jul 31, 2019
Fund Family
Lord Abbett Family of Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Unspecified

Performance

YTD+3.12%
1 Year+28.27%
3 Year+8.72%
5 Year+3.30%

Asset Allocation

Stocks: 96.38%
Cash: 1.69%
Other: 1.93%
See how much of LHCQX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report is $25, once. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co.8.89%
AZN:LNAstraZeneca PLC4.73%
GILDGilead Sciences4.25%
JNJJohnson & Johnson - Common3.19%
NKTRNektar Therapeutics3.17%
Top 10 Concentration: 37.55%Report Date: Apr 30, 2026
Download all 64 holdings for LHCQX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Unspecified
Latest Distribution
$1.47
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

LHCQX Mutual Fund Overview

LHCQX Mutual Fund (Lord Abbett Health Care Fund Class R3) is managed by Lord Abbett Family of Funds. LHCQX expense ratio is 1.28%, holding 64 positions across sectors including Health Care, Financials, Industrials. Inception date: 2019-07-31.

LHCQX performance shows a YTD return of 3.12%. The 1-year return is 28.27% and the 5-year return is 3.30%.

LHCQX top holdings include Eli Lilly & Co. (8.9%), AstraZeneca PLC (4.7%), Gilead Sciences (4.3%), Johnson & Johnson - Common (3.2%), Nektar Therapeutics (3.2%). Go to all LHCQX holdings, LHCQX sectors, or LHCQX dividends.

LHCQX can be compared against other funds. Use LHCQX overlap to find shared positions, or LHCQX vs another fund for a side-by-side view. LHCQX alternatives are available via the screener, along with tax-loss harvesting opportunities.